328 related articles for article (PubMed ID: 27215391)
1. Targeted therapy in ovarian cancer.
Lim HJ; Ledger W
Womens Health (Lond); 2016 Jun; 12(3):363-78. PubMed ID: 27215391
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies for treatment of recurrent ovarian cancer.
Grisham RN; Hyman DM; Iyer G
Clin Adv Hematol Oncol; 2014 Mar; 12(3):158-62. PubMed ID: 24927263
[TBL] [Abstract][Full Text] [Related]
3. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
[TBL] [Abstract][Full Text] [Related]
4. The role of targeted therapy in ovarian cancer.
Banerjee S; Kaye S
Eur J Cancer; 2011 Sep; 47 Suppl 3():S116-30. PubMed ID: 21943965
[TBL] [Abstract][Full Text] [Related]
5. Successes and limitations of targeted cancer therapy in ovarian cancer.
Damia G; Sessa C
Prog Tumor Res; 2014; 41():89-97. PubMed ID: 24727989
[TBL] [Abstract][Full Text] [Related]
6. Novel antiangiogenic therapies in ovarian cancer.
Stuckey A; Dizon DS
Womens Health (Lond); 2012 Jul; 8(4):447-53. PubMed ID: 22757735
[TBL] [Abstract][Full Text] [Related]
7. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
8. IGF system targeted therapy: Therapeutic opportunities for ovarian cancer.
Liefers-Visser JAL; Meijering RAM; Reyners AKL; van der Zee AGJ; de Jong S
Cancer Treat Rev; 2017 Nov; 60():90-99. PubMed ID: 28934637
[TBL] [Abstract][Full Text] [Related]
9. Targeted agents and combinations in ovarian cancer: where are we now?
McLachlan J; Lima JP; Dumas L; Banerjee S
Expert Rev Anticancer Ther; 2016; 16(4):441-54. PubMed ID: 26942837
[TBL] [Abstract][Full Text] [Related]
10. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
11. The future of targeted therapies in ovarian cancer.
Banerjee S; Gore M
Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer relapse: From the latest scientific evidence to the best practice.
Luvero D; Plotti F; Aloisia A; Montera R; Terranova C; Carlo De Cicco Nardone ; Scaletta G; Lopez S; Miranda A; Capriglione S; Gatti A; Pierluigi Benedetti Panici ; Angioli R
Crit Rev Oncol Hematol; 2019 Aug; 140():28-38. PubMed ID: 31176270
[TBL] [Abstract][Full Text] [Related]
13. New developments in molecular targeted therapy of ovarian cancer.
Guan LY; Lu Y
Discov Med; 2018 Nov; 26(144):219-229. PubMed ID: 30695681
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis: a promising therapeutic target for ovarian cancer.
Bamias A; Pignata S; Pujade-Lauraine E
Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
[TBL] [Abstract][Full Text] [Related]
15. [New drugs and targeted therapeutic agents in ovarian cancer].
de La Motte Rouge T; Petrella MC; Michels J; Even C; Balleyguier C; Duclos J; Mazeron R; Morice P; Pautier P; Lhommé C
Bull Cancer; 2009 Dec; 96(12):1215-24. PubMed ID: 19919916
[TBL] [Abstract][Full Text] [Related]
16. Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy.
Liang Z; Lu Z; Zhang Y; Shang D; Li R; Liu L; Zhao Z; Zhang P; Lin Q; Feng C; Zhang Y; Liu P; Tu Z; Liu H
Curr Cancer Drug Targets; 2019; 19(6):449-467. PubMed ID: 30306870
[TBL] [Abstract][Full Text] [Related]
17. Leveraging DNA repair deficiency in gynecologic oncology.
Walsh CS; Hodeib M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):24-31. PubMed ID: 26694829
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors in ovarian and other cancers.
Plummer R
Clin Adv Hematol Oncol; 2015 May; 13(5):285-7. PubMed ID: 26352770
[No Abstract] [Full Text] [Related]
19. Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy.
Gong H; Nie D; Li Z
Curr Cancer Drug Targets; 2020; 20(11):853-867. PubMed ID: 32807056
[TBL] [Abstract][Full Text] [Related]
20. Current and emerging treatment options in the management of advanced ovarian cancer.
Rodriguez-Freixinos V; Mackay HJ; Karakasis K; Oza AM
Expert Opin Pharmacother; 2016 Jun; 17(8):1063-76. PubMed ID: 26918413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
